---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-030565"
form_type: "8-K/A"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2022-11-21T23:59:59+00:00"
generated_at: "2026-06-21T15:05:56.658548+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Bioventus amends Q3 results with $189M impairment; cuts FY2022 guidance

## Summary
- Net loss of $145.7M ($1.76 loss per share) vs $2.3M loss in prior year; includes $189.2M non-cash impairment.
- Net sales of $128.7M, +18.2% YoY; organic sales down 0.5%.
- FY2022 guidance cut: net sales now $517-522M (prev $547.5-562.5M); Adj. EBITDA $75-79M (prev $94-104M).
- Non-GAAP EPS guidance lowered to $0.20-0.25 from $0.47-0.57.
- Company discontinued development of MOTYS drug candidate.

## SEC filing metadata
- accession: 0001628280-22-030565
- form_type: 8-K/A
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2022-11-21T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000162828022030565/0001628280-22-030565-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000162828022030565/bvs-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-030565
- JSON: https://secwatch.observer/filing/0001628280-22-030565.json
- Plain text: https://secwatch.observer/filing/0001628280-22-030565.txt

## Key facts
- Earnings Releases
  Bioventus Inc. reported financial results for the nine months ended October 1, 2022.
  - Period: the nine months ended October 1, 2022
  - Result: reported results
  source text: amended its previously announced financial results for the three and nine months ended October 1, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000162828022030565/0001628280-22-030565-index.htm
- Earnings Releases
  Bioventus Inc. reported the three months ended October 1, 2022 results: revenue $128.7 million, net income $145.7 million, EPS $1.76.
  - Period: the three months ended October 1, 2022
  - Revenue: $128.7 million
  - Net income: $145.7 million
  - EPS: $1.76
  - Result: reported results
  source text: • Net Sales of $128.7 million, up $19.8 million, or 18.2%, year-over-year as reported (19.1% constant currency*) and down (0.5%) organically* (0.3% constant currency*) • Net Loss of $145.7 million, compared to Net Loss of $2.3 million in prior-year period • Adjusted EBITDA* of $21.0 million, compared to $21.3 million in prior-year period • Loss per share of Class A common stock of $1.76, compared to $0.03 in prior-year period • Non-GAAP earnings per share of Class A common stock* of $0.06, compared to $0.19 in prior-year period
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000162828022030565/0001628280-22-030565-index.htm
- Earnings Releases
  Bioventus Inc. reported the twelve months ending December 31, 2022 results: revenue $517 million to $522 million, EPS $0.20 to $0.25. Guidance lowered.
  - Period: the twelve months ending December 31, 2022
  - Revenue: $517 million to $522 million
  - EPS: $0.20 to $0.25
  - Guidance: lowered
  - Result: guidance update
  source text: • Net sales of $517 million to $522 million, representing year-over-year growth of approximately 20% to 21%, representing an update to the prior guidance of $547.5 million to $562.5 million. • Adjusted EBITDA* of $75 million to $79 million, compared to $80.8 million for the year ended December 31, 2021, and representing an update from the prior guidance of $94 million to $104 million. • Non-GAAP EPS* of $0.20 to $0.25, compared to $0.75 for the year ended December 31, 2021, and representing an update from the prior guidance of $0.47 to $0.57.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000162828022030565/0001628280-22-030565-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.